Masatoshi Kudo

111PUBLICATIONS
350CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)EcohydrologyHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (111)

|Jul 28, 2026
Long-Term Real-World Evaluation of Tofacitinib's Effectiveness and Safety in Japan: Insights Into Optimal Timing for Dose Reduction.

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|May 29, 2026
Beyond Equivalence: Reconsidering the Role of EUS-Guided Gallbladder Drainage in the Post-ERCP Failure Algorithm.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 13, 2026
Diagnostic Utility of Endoscopic Features and Endoscopic Ultrasonography for Ulcerative Colitis-Associated Neoplasia: A Retrospective Study on the Role of Endoscopic Submucosal Dissection as a Total Biopsy.

Pageof 19

Frequent Collaborators

26 joint publications

Tomoko Aoki

26 joint publications

Takeshi Hatanaka

26 joint publications

Hidenori Toyoda

25 joint publications

Satoru Kakizaki